

# **SNX1** Antibody

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP51531

#### **Product Information**

Application WB Primary Accession Q13596

**Reactivity** Human, Mouse, Rat

HostRabbitClonalityPolyclonalCalculated MW59070

#### **Additional Information**

Gene ID 6642

Other Names Sorting nexin-1, SNX1

**Dilution** WB~~1:1000

Format 0.01M PBS, pH 7.2, 0.09% (W/V) Sodium azide, Glycerol 50%

Storage Store at -20 °C.Stable for 12 months from date of receipt

### **Protein Information**

Name SNX1

**Function** Involved in several stages of intracellular trafficking. Interacts with

membranes containing phosphatidylinositol 3-phosphate (PtdIns(3P)) or phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) (PubMed:12198132). Acts in part as component of the retromer membrane- deforming SNX-BAR subcomplex. The SNX-BAR retromer mediates retrograde transport of cargo proteins from endosomes to the trans-Golgi network (TGN) and is involved in endosome-to-plasma membrane transport for cargo protein recycling. The SNX-BAR subcomplex functions to deform the donor membrane into a tubular profile called endosome-to-TGN transport carrier (ETC) (Probable). Can sense membrane curvature and has in vitro vesicle-to-membrane remodeling activity (PubMed:19816406, PubMed:23085988). Involved in retrograde endosome-to-TGN transport of lysosomal enzyme receptors (IGF2R, M6PR and SORT1) and Shiginella dysenteria toxin stxB. Plays a role in targeting ligand-activated EGFR to the lysosomes for degradation after

endocytosis from the cell surface and release from the Golgi

(PubMed:<u>12198132</u>, PubMed:<u>15498486</u>, PubMed:<u>17101778</u>, PubMed:<u>17550970</u>, PubMed:<u>18088323</u>, PubMed:<u>21040701</u>). Involvement in retromer-independent endocytic trafficking of P2RY1 and lysosomal degradation of protease-activated receptor-1/F2R (PubMed:<u>16407403</u>,

PubMed:<u>20070609</u>). Promotes KALRN- and RHOG-dependent but retromer-independent membrane remodeling such as lamellipodium formation; the function is dependent on GEF activity of KALRN (PubMed:<u>20604901</u>). Required for endocytosis of DRD5 upon agonist stimulation but not for basal receptor trafficking (PubMed:<u>23152498</u>).

#### **Cellular Location**

Endosome membrane; Peripheral membrane protein; Cytoplasmic side. Golgi apparatus, trans-Golgi network membrane; Peripheral membrane protein; Cytoplasmic side. Early endosome membrane; Peripheral membrane protein; Cytoplasmic side. Cell projection, lamellipodium. Note=Enriched on tubular elements of the early endosome membrane. Binds preferentially to highly curved membranes enriched in phosphatidylinositol 3-phosphate (PtdIns(3P)) or phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) (PubMed:15498486). Colocalized with SORT1 to tubular endosomal membrane structures called endosome-to-TGN transport carriers (ETCs) which are budding from early endosome vacuoles just before maturing into late endosome vacuoles (PubMed:18088323). Colocalizes with DNAJC13 and Shiginella dysenteria toxin stxB on early endosomes (PubMed:19874558) Colocalized with F-actin at the leading edge of lamellipodia in a KALRN-dependent manner (PubMed:20604901).

## **Background**

May be involved in several stages of intracellular trafficking. Plays a role in targeting ligand-activated EGFR to the lysosomes for degradation after endocytosis from the cell surface and release from the Golgi. Component of the retromer complex, a complex required to retrieve lysosomal enzyme receptors (IGF2R and M6PR) from endosomes to the trans-Golgi network. Interacts with membranes containing phosphatidylinositol 3- phosphate (PtdIns(3P)) or phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2).

#### References

Kurten R.C., et al. Science 272:1008-1010(1996). Haft C.R., et al. Mol. Cell. Biol. 18:7278-7287(1998). Kalnine N., et al. Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases. Ota T., et al. Nat. Genet. 36:40-45(2004). Zody M.C., et al. Nature 440:671-675(2006).

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.